Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

Martín, Miguel; Ruı́z, Amparo; Ruíz-Borrego, Manuel; Barnadas, Agustí; González, Sónia; Calvo, Lourdes; Vila, Mireia Margelí; Antón, Antonio; Rodríguez-Lescure, Álvaro; Seguí-Palmer, Miguel Ángel; Muñoz-Mateu, Montserrat; Ribugent, Joan Dorca; López‐Vega, José Manuel; Jara, Carlos; Espinosa, Enrique; Fernández, César Mendiola; Andrés, Raquel; Ribelles, Nuria; Plazaola, Arrate; Sánchez‐Rovira, Pedro; Bofill, Javier Salvador; Crespo, Carmen; Carabantes, F.; Servitja, Sònia; Chacón, José Ignacio; Rodrı́guez, César; Hernando, Blanca; Álvarez, Isabel; Carrasco, Eva; Lluch, Aña

doi:10.1200/jco.2012.46.9841

Cited by 54 publications

(32 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Severe neutropaenia occurs in about one fifth of patients on FAC. [29] Therapy had to be discontinued in 3 patients in the current study due to neutropaenia, including only 2 of 27 HIV-infected patients.…”

Section: Discussionmentioning

confidence: 99%

The effect of HIV infection on the surgical, chemo- and radiotherapy management of breast cancer. A prospective cohort study

Phakathi

Basson

Karusseit

et al. 2016

International Journal of Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The effect of HIV infection on the surgical, chemo- and radiotherapy management of breast cancer. A prospective cohort study

Phakathi

Basson

Karusseit

et al. 2016

International Journal of Surgery

View full text Add to dashboard Cite

“…Our retrospective experience herein included 97 patients who fit this criteria with a median age of 52 and median follow-up of 66 months. There have been 7 recurrences (7.2%) which compares favorably to both the fluorouracil, doxorubicin, and cyclophosphamide (FAC) arm and FAC plus weekly paclitaxel (wP) arm, which had recurrence rates of 9.3% and 7%, respectively [19]. Our incidence of grade 3 and 4 neutropenia in this group was 18.5%, which is lower than the 21.8% reported for FAC and 25.4% reported for FAC-wP.…”

Section: Discussionmentioning

confidence: 83%

Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New

Cho

Schwemm

Rubinstein

et al. 2015

Clinical Breast Cancer

View full text Add to dashboard Cite

Commonly used adjuvant systemic therapies harbor high rates of severe short-term and long-term side effects but are often justified to patients because of curative intent in early stage breast cancer. One of the oldest and least toxic adjuvant regimens, oral cyclophosphamide given with intravenous methotrexate and 5-fluourouracil (CMF) has been largely abandoned because of the perception that it underperforms for survival outcomes compared to modern regimens containing anthracycline and/or taxanes. To address this misperception, we performed a review of all consecutive breast cancer patients at the Seattle Cancer Care Alliance over the past decade receiving 6 months of adjuvant CMF as their sole chemotherapy regimen and determined rates for relapse-free survival (RFS), overall survival (OS), and major organ toxicity. From January 2003 to August 2013, 248 patients (median age of 52 years at the start of chemotherapy) met criteria for inclusion in this series and had a median follow-up of 67 months. RFS and OS at 5 years was 94.5% (91.3-97.9%) and 98% (96-100%), respectively. The only major organ toxicity occurring in more than 5% of patients was Grade III neutropenia (18.1%). One patient died during therapy from pneumocystis pneumonia attributed to previously undiagnosed AIDS. In a modern cohort of patients thoroughly characterized for grade and hormone receptor status, CMF was a well-tolerated and effective adjuvant regimen for early stage breast cancer and should be considered for appropriately selected patients.

show abstract

“…A Spanish group published the results from the GEICAM/2003-02 study, comparing FAC, and FAC followed by weekly paclitaxel for node negative high-risk patients. In this study, additional weekly paclitaxel for 8 weeks added a 2.7% improvement in PFS at 63.3 months follow-up 28 .…”

Section: Adjuvant Treatment In Hormone Receptor Positive Breast Cancermentioning

confidence: 81%

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy

et al. 2014

View full text Add to dashboard Cite

Breast cancer is the most commonly diagnosed cancer in women. The latest world cancer statistics calculated by the International Agency for Research on Cancer (IARC) revealed that 1,677,000 women were diagnosed with breast cancer in 2012 and 577,000 died. The TNM classification of malignant tumor (TNM) is the most commonly used staging system for breast cancer. Breast cancer is a group of very heterogeneous diseases. The molecular subtype of breast cancer carries important predictive and prognostic values, and thus has been incorporated in the basic initial process of breast cancer assessment/diagnosis. Molecular subtypes of breast cancers are divided into human epidermal growth factor receptor 2 positive (HER2 +), hormone receptor positive (estrogen or progesterone +), both positive, and triple negative breast cancer. By virtue of early detection via mammogram, the majority of breast cancers in developed parts of world are diagnosed in the early stage of the disease. Early stage breast cancers can be completely resected by surgery. Over time however, the disease may come back even after complete resection, which has prompted the development of an adjuvant therapy. Surgery followed by adjuvant treatment has been the gold standard for breast cancer treatment for a long time. More recently, neoadjuvant treatment has been recognized as an important strategy in biomarker and target evaluation. It is clinically indicated for patients with large tumor size, high nodal involvement, an inflammatory component, or for those wish to preserve remnant breast tissue. Here we review the most up to date conventional and developing treatments for different subtypes of early stage breast cancer.

show abstract

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

Abstract: For patients with high-risk node-negative BC, the adjuvant FAC-wP regimen was associated with a small but significant improvement in DFS compared with FAC therapy, in addition to manageable toxicity, especially regarding long-term cardiac effects.

Cited by 54 publications

References 17 publications

The effect of HIV infection on the surgical, chemo- and radiotherapy management of breast cancer. A prospective cohort study

The effect of HIV infection on the surgical, chemo- and radiotherapy management of breast cancer. A prospective cohort study

Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy

Contact Info

Product

Resources

About